Cannabix Technologies Inc. reported that early testing by Omega Laboratories Inc. with the Company?s marijuana breathalyzer technology have garnered positive results. Omega has commenced pre-validation scoping work to establish limits of detection (LOD) and limits of quantification (LOQ) as well as the cutoff level for the detection of delta-9 THC (primary psychoactive ingredient in cannabis) in breath. Recently, Cannabix entered into a strategic partnership and development agreement with Omega Laboratories to advance the development and commercialization of the Cannabix marijuana breathalyzer technology.

Highlights: Omega scientists have established a delta-9 THC calibration curve with samples obtained from the Cannabix Breath Collection Unit (BCU) for the purposes of quantification using Omega?s preexisting and well-established extraction and detection processes; Thus far, Omega scientists have been able to detect and quantify delta-9 THC in the low picogram range ? a level of detection low enough for detecting drug compounds in breath; Omega scientists have consistently detected and quantified delta-9 THC from breath samples collected from subjects utilizing the Cannabix BCU; and Omega scientists have developed a test method for a breath sample that successfully detects and differentiates between delta-9 THC, delta-8 THC, CBN and CBD. Cannabix and Omega have begun working together on multiple fronts including hardware refinement, marketing and preparing numerous validation studies.